Korea Approves Second Biosimilar Infliximab
This article was originally published in PharmAsia News
After receiving the green light for its version of etanercept a few months ago, Samsung Bioepis has gained a second biosimilar regulatory approval in South Korea as it aims to catch up with frontrunner Celltrion. Renflexis is the second infliximab biosimilar to be approved in the country after Celltrion's Remsima.
Register for our free email digests: